EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Consideration of Osteoporosis Risk in Selecting Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease Patients: Budesonide vs Fluticasone?

Ali Erol, Feridun Gürlek, Fatih Alp, Sümeyye Yaylacı, Enes Kocaman, Orkun- -Terzi, Şule Bilgin Kızıltaş, Mehmet Karaçalı, Neslihan Baykara Erol, Muhammed Fatih Şahin, Aydın Dursun

European Journal of Therapeutics · 27.03.2026 · 32 (2) · 227-234

DOI: 10.58600/eurjther2941 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Therapeutics, online erschienen am 27.03.2026. Verfasst von Ali Erol und 10 weiteren Autor:innen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The use of medium and low-dose inhaled corticosteroids (ICS) did not increase the risk of osteoporosis in individuals with chronic obstructive pulmonary disease (COPD). The goal is to look at the risk of osteoporosis that comes with Budesonide and Fluticasone when choosing ICS for people with COPD, since this group of people is more likely to get osteoporosis.

Methods

Patients with Stage E COPD who were on ICS and came to a tertiary healthcare facility between January 2024 and January 2025 were included. There were three groups in the trial: people with COPD who were taking inhaled budesonide, those who were on fluticasone, and a control group.

Results

The study comprised 122 participants: 16 COPD patients utilizing inhaled fluticasone, 16 COPD patients utilizing inhaled budesonide, and 90 individuals in the control group. The mean age of the study participants was 72.79 years; the mean age of the fluticasone group was 74.69 years, the mean age of the budesonide group was 73.19 years, and the mean age of the control group was 72.38 years. The groups exhibit no significant difference for osteoporosis (p>0.05). No significant difference was seen between the groups for the duration and intensity of ICS use (p>0.05).

Conclusion

In individuals with COPD, the administration of budesonide and fluticasone as inhaled corticosteroid options has not elevated the risk of osteoporosis.

Zitieren

APA

Erol, A., Gürlek, F., Alp, F., Yaylacı, S., Kocaman, E., -Terzi, O., Kızıltaş, Ş. B., Karaçalı, M., Erol, N. B., Şahin, M. F., & Dursun, A. (2026). Consideration of Osteoporosis Risk in Selecting Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease Patients: Budesonide vs Fluticasone?. European Journal of Therapeutics, 32(2), 227-234. https://doi.org/10.58600/eurjther2941

Vancouver

Erol A, Gürlek F, Alp F, Yaylacı S, Kocaman E, -Terzi O, et al. Consideration of Osteoporosis Risk in Selecting Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease Patients: Budesonide vs Fluticasone?. European Journal of Therapeutics. 2026;32(2):227-234. doi:10.58600/eurjther2941

BibTeX
@article{Erol2026,
  author = {Erol, Ali and Gürlek, Feridun and Alp, Fatih and Yaylacı, Sümeyye and Kocaman, Enes and -Terzi, Orkun- and Kızıltaş, Şule Bilgin and Karaçalı, Mehmet and Erol, Neslihan Baykara and Şahin, Muhammed Fatih and Dursun, Aydın},
  title = {Consideration of Osteoporosis Risk in Selecting Inhaled Corticosteroids for Chronic Obstructive Pulmonary Disease Patients: Budesonide vs Fluticasone?},
  journal = {European Journal of Therapeutics},
  year = {2026},
  volume = {32},
  number = {2},
  pages = {227--234},
  doi = {10.58600/eurjther2941}
}
Kostenlos starten →